phenytoin	Oxycodone	11	10	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		8183	7804	D010672	D010098
phenytoin	Oxycodone	11	10	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		8183	7804	D010672	D010098
phenytoin	Oxycodone	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		8183	7804	D010672	D010098
phenytoin	Oxycodone	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		8183	7804	D010672	D010098
phenytoin	rifampin	11	10	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		8183	9384	D010672	9384
phenytoin	rifampin	11	10	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		8183	9384	D010672	9384
phenytoin	rifampin	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		8183	9384	D010672	9384
phenytoin	rifampin	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		8183	9384	D010672	9384
phenytoin	oxycodone	11	10	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		8183	7804	D010672	D010098
phenytoin	oxycodone	11	10	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		8183	7804	D010672	D010098
phenytoin	oxycodone	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		8183	7804	D010672	D010098
phenytoin	oxycodone	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		8183	7804	D010672	D010098
phenytoin	carbamazepine	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		8183	2002	D010672	D002220
phenytoin	carbamazepine	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		8183	2002	D010672	D002220
ketoconazole	Oxycodone	7	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		6135	7804	D007654	D010098
ketoconazole	Oxycodone	7	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		6135	7804	D007654	D010098
ketoconazole	p450	7	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		6135	none	D007654	none
ketoconazole	p450	7	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		6135	none	D007654	none
ketoconazole	ritonavir	7	7	false	none	Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		6135	85762	D007654	D019438
ketoconazole	ritonavir	7	7	false	none	Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		6135	85762	D007654	D019438
ketoconazole	voriconazole	7	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		6135	121243	D007654	121243
ketoconazole	voriconazole	7	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		6135	121243	D007654	121243
ketoconazole	oxycodone	7	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		6135	7804	D007654	D010098
ketoconazole	oxycodone	7	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		6135	7804	D007654	D010098
ketoconazole	erythromycin	7	7	false	none	Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		6135	4053	D007654	D004917
ketoconazole	erythromycin	7	7	false	none	Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		6135	4053	D007654	D004917
Oxycodone	p450	4	6	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	none	D010098	none
Oxycodone	p450	4	6	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	none	D010098	none
Oxycodone	p450	6	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	none	D010098	none
Oxycodone	p450	6	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	none	D010098	none
Oxycodone	p450	14	14	false	none	[see Clinical Pharmacology (12.3)]    CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	p450	14	14	false	none	[see Clinical Pharmacology (12.3)]    CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	none	D010098	none
Oxycodone	maois	17	17	false	none	7.5 Monoamine Oxidase Inhibitors (MAOIs)    No specific interaction between oxycodone and monoamine oxidase inhibitors has been observed, but caution in the use of any opioid in patients taking this class of drugs is appropriate.  		7804	none	D010098	none
Oxycodone	maois	17	17	false	none	7.5 Monoamine Oxidase Inhibitors (MAOIs)    No specific interaction between oxycodone and monoamine oxidase inhibitors has been observed, but caution in the use of any opioid in patients taking this class of drugs is appropriate.  		7804	none	D010098	none
Oxycodone	ritonavir	6	7	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		7804	85762	D010098	D019438
Oxycodone	ritonavir	6	7	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		7804	85762	D010098	D019438
Oxycodone	pentazocine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	8001	D010098	D010423
Oxycodone	pentazocine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	8001	D010098	D010423
Oxycodone	pentazocine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	8001	D010098	D010423
Oxycodone	pentazocine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	8001	D010098	D010423
Oxycodone	pentazocine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	8001	D010098	D010423
Oxycodone	pentazocine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	8001	D010098	D010423
Oxycodone	pentazocine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	8001	D010098	D010423
Oxycodone	pentazocine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	8001	D010098	D010423
Oxycodone	voriconazole	4	6	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	121243	D010098	121243
Oxycodone	voriconazole	4	6	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	121243	D010098	121243
Oxycodone	voriconazole	6	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	121243	D010098	121243
Oxycodone	voriconazole	6	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	121243	D010098	121243
Oxycodone	rifampin	10	10	true	positive	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  		7804	9384	D010098	9384
Oxycodone	rifampin	10	10	true	positive	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  		7804	9384	D010098	9384
Oxycodone	rifampin	10	11	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		7804	9384	D010098	9384
Oxycodone	rifampin	10	11	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		7804	9384	D010098	9384
Oxycodone	rifampin	11	10	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		7804	9384	D010098	9384
Oxycodone	rifampin	11	10	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		7804	9384	D010098	9384
Oxycodone	rifampin	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		7804	9384	D010098	9384
Oxycodone	rifampin	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		7804	9384	D010098	9384
Oxycodone	oxymorphone	14	14	false	none	[see Clinical Pharmacology (12.3)]    CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	7814	D010098	7814
Oxycodone	oxymorphone	14	14	false	none	[see Clinical Pharmacology (12.3)]    CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7804	7814	D010098	7814
Oxycodone	nalbuphine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
Oxycodone	nalbuphine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
Oxycodone	nalbuphine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
Oxycodone	nalbuphine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
Oxycodone	nalbuphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
Oxycodone	nalbuphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
Oxycodone	nalbuphine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	7238	D010098	7238
Oxycodone	nalbuphine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	7238	D010098	7238
Oxycodone	alcohol	2	1	false	none	7 DRUG INTERACTIONS    7.1 CNS Depressants  Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.  Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  		7804	none	D010098	none
Oxycodone	alcohol	2	1	false	none	7 DRUG INTERACTIONS    7.1 CNS Depressants  Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.  Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  		7804	none	D010098	none
Oxycodone	alcohol	3	1	false	none	7 DRUG INTERACTIONS    7.1 CNS Depressants  Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.  Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  		7804	none	D010098	none
Oxycodone	alcohol	3	1	false	none	7 DRUG INTERACTIONS    7.1 CNS Depressants  Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.  Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  		7804	none	D010098	none
Oxycodone	buprenorphine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
Oxycodone	buprenorphine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
Oxycodone	buprenorphine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
Oxycodone	buprenorphine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
Oxycodone	buprenorphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
Oxycodone	buprenorphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
Oxycodone	buprenorphine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	0	D010098	D002047
Oxycodone	buprenorphine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	0	D010098	D002047
Oxycodone	carbamazepine	10	11	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		7804	2002	D010098	D002220
Oxycodone	carbamazepine	10	11	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		7804	2002	D010098	D002220
Oxycodone	carbamazepine	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		7804	2002	D010098	D002220
Oxycodone	carbamazepine	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		7804	2002	D010098	D002220
Oxycodone	butorphanol	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
Oxycodone	butorphanol	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
Oxycodone	butorphanol	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
Oxycodone	butorphanol	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
Oxycodone	butorphanol	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
Oxycodone	butorphanol	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
Oxycodone	butorphanol	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	1841	D010098	D002077
Oxycodone	butorphanol	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	1841	D010098	D002077
Oxycodone	erythromycin	6	7	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		7804	4053	D010098	D004917
Oxycodone	erythromycin	6	7	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		7804	4053	D010098	D004917
oxycodone hydrochloride	p450	4	6	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	none	D010098	none
oxycodone hydrochloride	p450	4	6	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	none	D010098	none
oxycodone hydrochloride	pentazocine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	8001	D010098	D010423
oxycodone hydrochloride	pentazocine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	8001	D010098	D010423
oxycodone hydrochloride	pentazocine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	8001	D010098	D010423
oxycodone hydrochloride	pentazocine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	8001	D010098	D010423
oxycodone hydrochloride	pentazocine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	8001	D010098	D010423
oxycodone hydrochloride	pentazocine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	8001	D010098	D010423
oxycodone hydrochloride	voriconazole	4	6	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	121243	D010098	121243
oxycodone hydrochloride	voriconazole	4	6	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	121243	D010098	121243
oxycodone hydrochloride	oxycodone	2	2	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  		D010098	D010098
oxycodone hydrochloride	oxycodone	2	3	true	positive	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  		D010098	D010098
oxycodone hydrochloride	oxycodone	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		D010098	D010098
oxycodone hydrochloride	oxycodone	3	2	true	positive	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  		D010098	D010098
oxycodone hydrochloride	oxycodone	3	3	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  		D010098	D010098
oxycodone hydrochloride	oxycodone	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		D010098	D010098
oxycodone hydrochloride	oxycodone	4	2	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		D010098	D010098
oxycodone hydrochloride	oxycodone	4	3	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		D010098	D010098
oxycodone hydrochloride	oxycodone	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		D010098	D010098
oxycodone hydrochloride	oxycodone	4	6	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		D010098	D010098
oxycodone hydrochloride	nalbuphine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
oxycodone hydrochloride	nalbuphine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
oxycodone hydrochloride	nalbuphine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
oxycodone hydrochloride	nalbuphine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
oxycodone hydrochloride	nalbuphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
oxycodone hydrochloride	nalbuphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
oxycodone hydrochloride	alcohol	2	1	false	none	7 DRUG INTERACTIONS    7.1 CNS Depressants  Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.  Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  		7804	none	D010098	none
oxycodone hydrochloride	alcohol	2	1	false	none	7 DRUG INTERACTIONS    7.1 CNS Depressants  Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.  Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  		7804	none	D010098	none
oxycodone hydrochloride	alcohol	3	1	false	none	7 DRUG INTERACTIONS    7.1 CNS Depressants  Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.  Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  		7804	none	D010098	none
oxycodone hydrochloride	alcohol	3	1	false	none	7 DRUG INTERACTIONS    7.1 CNS Depressants  Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.  Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  		7804	none	D010098	none
oxycodone hydrochloride	buprenorphine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
oxycodone hydrochloride	buprenorphine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
oxycodone hydrochloride	buprenorphine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
oxycodone hydrochloride	buprenorphine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
oxycodone hydrochloride	buprenorphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
oxycodone hydrochloride	buprenorphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
oxycodone hydrochloride	butorphanol	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
oxycodone hydrochloride	butorphanol	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
oxycodone hydrochloride	butorphanol	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
oxycodone hydrochloride	butorphanol	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
oxycodone hydrochloride	butorphanol	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
oxycodone hydrochloride	butorphanol	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
p450	ritonavir	6	7	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		none	85762	none	D019438
p450	ritonavir	6	7	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		none	85762	none	D019438
p450	pentazocine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		none	8001	none	D010423
p450	pentazocine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		none	8001	none	D010423
p450	voriconazole	6	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		none	121243	none	121243
p450	voriconazole	6	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		none	121243	none	121243
p450	Oxycodone hydrochloride	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		none	7804	none	D010098
p450	Oxycodone hydrochloride	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		none	7804	none	D010098
p450	oxymorphone	14	14	false	none	[see Clinical Pharmacology (12.3)]    CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		none	7814	none	7814
p450	oxymorphone	14	14	false	none	[see Clinical Pharmacology (12.3)]    CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		none	7814	none	7814
p450	oxycodone	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		none	7804	none	D010098
p450	oxycodone	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		none	7804	none	D010098
p450	oxycodone	6	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		none	7804	none	D010098
p450	oxycodone	6	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		none	7804	none	D010098
p450	oxycodone	14	14	false	none	[see Clinical Pharmacology (12.3)]    CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		none	7804	none	D010098
p450	oxycodone	14	14	false	none	[see Clinical Pharmacology (12.3)]    CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		none	7804	none	D010098
p450	nalbuphine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		none	7238	none	7238
p450	nalbuphine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		none	7238	none	7238
p450	buprenorphine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		none	0	none	D002047
p450	buprenorphine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		none	0	none	D002047
p450	butorphanol	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		none	1841	none	D002077
p450	butorphanol	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		none	1841	none	D002077
p450	erythromycin	6	7	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		none	4053	none	D004917
p450	erythromycin	6	7	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		none	4053	none	D004917
maois	oxycodone	17	17	false	none	7.5 Monoamine Oxidase Inhibitors (MAOIs)    No specific interaction between oxycodone and monoamine oxidase inhibitors has been observed, but caution in the use of any opioid in patients taking this class of drugs is appropriate.  		none	7804	none	D010098
maois	oxycodone	17	17	false	none	7.5 Monoamine Oxidase Inhibitors (MAOIs)    No specific interaction between oxycodone and monoamine oxidase inhibitors has been observed, but caution in the use of any opioid in patients taking this class of drugs is appropriate.  		none	7804	none	D010098
ritonavir	voriconazole	7	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		85762	121243	D019438	121243
ritonavir	voriconazole	7	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		85762	121243	D019438	121243
ritonavir	oxycodone	7	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		85762	7804	D019438	D010098
ritonavir	oxycodone	7	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		85762	7804	D019438	D010098
ritonavir	erythromycin	7	7	false	none	Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		85762	4053	D019438	D004917
ritonavir	erythromycin	7	7	false	none	Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		85762	4053	D019438	D004917
pentazocine	voriconazole	4	6	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		8001	121243	D010423	121243
pentazocine	voriconazole	4	6	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		8001	121243	D010423	121243
pentazocine	Oxycodone hydrochloride	4	2	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	7804	D010423	D010098
pentazocine	Oxycodone hydrochloride	4	2	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	7804	D010423	D010098
pentazocine	Oxycodone hydrochloride	4	3	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	7804	D010423	D010098
pentazocine	Oxycodone hydrochloride	4	3	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	7804	D010423	D010098
pentazocine	Oxycodone hydrochloride	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	7804	D010423	D010098
pentazocine	Oxycodone hydrochloride	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	7804	D010423	D010098
pentazocine	oxycodone	4	2	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	7804	D010423	D010098
pentazocine	oxycodone	4	2	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	7804	D010423	D010098
pentazocine	oxycodone	4	3	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	7804	D010423	D010098
pentazocine	oxycodone	4	3	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	7804	D010423	D010098
pentazocine	oxycodone	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	7804	D010423	D010098
pentazocine	oxycodone	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	7804	D010423	D010098
pentazocine	oxycodone	4	6	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		8001	7804	D010423	D010098
pentazocine	oxycodone	4	6	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		8001	7804	D010423	D010098
pentazocine	nalbuphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	7238	D010423	7238
pentazocine	nalbuphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	7238	D010423	7238
pentazocine	buprenorphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	0	D010423	D002047
pentazocine	buprenorphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	0	D010423	D002047
pentazocine	butorphanol	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	1841	D010423	D002077
pentazocine	butorphanol	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		8001	1841	D010423	D002077
voriconazole	Oxycodone hydrochloride	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		121243	7804	121243	D010098
voriconazole	Oxycodone hydrochloride	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		121243	7804	121243	D010098
voriconazole	oxycodone	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		121243	7804	121243	D010098
voriconazole	oxycodone	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		121243	7804	121243	D010098
voriconazole	oxycodone	6	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		121243	7804	121243	D010098
voriconazole	oxycodone	6	6	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		121243	7804	121243	D010098
voriconazole	nalbuphine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		121243	7238	121243	7238
voriconazole	nalbuphine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		121243	7238	121243	7238
voriconazole	buprenorphine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		121243	0	121243	D002047
voriconazole	buprenorphine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		121243	0	121243	D002047
voriconazole	butorphanol	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		121243	1841	121243	D002077
voriconazole	butorphanol	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		121243	1841	121243	D002077
voriconazole	erythromycin	6	7	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		121243	4053	121243	D004917
voriconazole	erythromycin	6	7	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		121243	4053	121243	D004917
Oxycodone hydrochloride	oxycodone	2	2	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  		D010098	D010098
Oxycodone hydrochloride	oxycodone	2	3	true	positive	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  		D010098	D010098
Oxycodone hydrochloride	oxycodone	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		D010098	D010098
Oxycodone hydrochloride	oxycodone	3	2	true	positive	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  		D010098	D010098
Oxycodone hydrochloride	oxycodone	3	3	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  		D010098	D010098
Oxycodone hydrochloride	oxycodone	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		D010098	D010098
Oxycodone hydrochloride	oxycodone	4	2	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		D010098	D010098
Oxycodone hydrochloride	oxycodone	4	3	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		D010098	D010098
Oxycodone hydrochloride	oxycodone	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		D010098	D010098
Oxycodone hydrochloride	oxycodone	4	6	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		D010098	D010098
Oxycodone hydrochloride	nalbuphine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
Oxycodone hydrochloride	nalbuphine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
Oxycodone hydrochloride	nalbuphine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
Oxycodone hydrochloride	nalbuphine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
Oxycodone hydrochloride	nalbuphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
Oxycodone hydrochloride	nalbuphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
Oxycodone hydrochloride	alcohol	2	1	false	none	7 DRUG INTERACTIONS    7.1 CNS Depressants  Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.  Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  		7804	none	D010098	none
Oxycodone hydrochloride	alcohol	2	1	false	none	7 DRUG INTERACTIONS    7.1 CNS Depressants  Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.  Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  		7804	none	D010098	none
Oxycodone hydrochloride	alcohol	3	1	false	none	7 DRUG INTERACTIONS    7.1 CNS Depressants  Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.  Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  		7804	none	D010098	none
Oxycodone hydrochloride	alcohol	3	1	false	none	7 DRUG INTERACTIONS    7.1 CNS Depressants  Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.  Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  		7804	none	D010098	none
Oxycodone hydrochloride	buprenorphine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
Oxycodone hydrochloride	buprenorphine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
Oxycodone hydrochloride	buprenorphine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
Oxycodone hydrochloride	buprenorphine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
Oxycodone hydrochloride	buprenorphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
Oxycodone hydrochloride	buprenorphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
Oxycodone hydrochloride	butorphanol	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
Oxycodone hydrochloride	butorphanol	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
Oxycodone hydrochloride	butorphanol	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
Oxycodone hydrochloride	butorphanol	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
Oxycodone hydrochloride	butorphanol	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
Oxycodone hydrochloride	butorphanol	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
rifampin	oxycodone	10	10	true	positive	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  		9384	7804	9384	D010098
rifampin	oxycodone	10	10	true	positive	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  		9384	7804	9384	D010098
rifampin	oxycodone	10	11	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		9384	7804	9384	D010098
rifampin	oxycodone	10	11	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		9384	7804	9384	D010098
rifampin	oxycodone	11	10	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		9384	7804	9384	D010098
rifampin	oxycodone	11	10	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		9384	7804	9384	D010098
rifampin	oxycodone	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		9384	7804	9384	D010098
rifampin	oxycodone	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		9384	7804	9384	D010098
rifampin	carbamazepine	10	11	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		9384	2002	9384	D002220
rifampin	carbamazepine	10	11	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		9384	2002	9384	D002220
rifampin	carbamazepine	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		9384	2002	9384	D002220
rifampin	carbamazepine	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		9384	2002	9384	D002220
oxymorphone	oxycodone	14	14	false	none	[see Clinical Pharmacology (12.3)]    CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7814	7804	7814	D010098
oxymorphone	oxycodone	14	14	false	none	[see Clinical Pharmacology (12.3)]    CYP2D6 Inhibitors  Oxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6.  		7814	7804	7814	D010098
oxycodone	nalbuphine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
oxycodone	nalbuphine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
oxycodone	nalbuphine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
oxycodone	nalbuphine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
oxycodone	nalbuphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
oxycodone	nalbuphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	7238	D010098	7238
oxycodone	nalbuphine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	7238	D010098	7238
oxycodone	nalbuphine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	7238	D010098	7238
oxycodone	alcohol	2	1	false	none	7 DRUG INTERACTIONS    7.1 CNS Depressants  Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.  Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  		7804	none	D010098	none
oxycodone	alcohol	2	1	false	none	7 DRUG INTERACTIONS    7.1 CNS Depressants  Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.  Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  		7804	none	D010098	none
oxycodone	alcohol	3	1	false	none	7 DRUG INTERACTIONS    7.1 CNS Depressants  Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.  Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  		7804	none	D010098	none
oxycodone	alcohol	3	1	false	none	7 DRUG INTERACTIONS    7.1 CNS Depressants  Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.  Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  		7804	none	D010098	none
oxycodone	buprenorphine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
oxycodone	buprenorphine	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
oxycodone	buprenorphine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
oxycodone	buprenorphine	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
oxycodone	buprenorphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
oxycodone	buprenorphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	0	D010098	D002047
oxycodone	buprenorphine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	0	D010098	D002047
oxycodone	buprenorphine	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	0	D010098	D002047
oxycodone	carbamazepine	10	11	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		7804	2002	D010098	D002220
oxycodone	carbamazepine	10	11	false	none	[see Clinical Pharmacology (12.3)]    CYP3A4 Inducers  A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.  Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		7804	2002	D010098	D002220
oxycodone	carbamazepine	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		7804	2002	D010098	D002220
oxycodone	carbamazepine	11	11	false	none	Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone.  		7804	2002	D010098	D002220
oxycodone	butorphanol	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
oxycodone	butorphanol	2	4	false	none	Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents.  7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
oxycodone	butorphanol	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
oxycodone	butorphanol	3	4	false	none	7.2 Muscle Relaxants  Oxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.  7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
oxycodone	butorphanol	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
oxycodone	butorphanol	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7804	1841	D010098	D002077
oxycodone	butorphanol	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	1841	D010098	D002077
oxycodone	butorphanol	6	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.  7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  		7804	1841	D010098	D002077
oxycodone	erythromycin	6	7	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		7804	4053	D010098	D004917
oxycodone	erythromycin	6	7	false	none	7.4 Agents Affecting Cytochrome P450 Enzymes    CYP3A4 Inhibitors  A published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.  Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects.  		7804	4053	D010098	D004917
nalbuphine	buprenorphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7238	0	7238	D002047
nalbuphine	buprenorphine	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7238	0	7238	D002047
nalbuphine	butorphanol	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7238	1841	7238	D002077
nalbuphine	butorphanol	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		7238	1841	7238	D002077
buprenorphine	butorphanol	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		0	1841	D002047	D002077
buprenorphine	butorphanol	4	4	false	none	7.3 Mixed Agonist/Antagonist Opioid Analgesics  Do not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride.  		0	1841	D002047	D002077
